News

About RPS-Asklep Inc.

To meet the increasing needs of global drug development, Asklep provides clinical development services in East Asia with offices across Japan, China, Taiwan, and Korea. RPS provides unique global outsourcing solutions from its accumulated knowledge and knowhow of multinational trials.

This exclusive collaboration will combine RPS’s global solutions and Asklep’s localized solutions to create a new service domain, with expectations of becoming a game changer in the CRO business in Japan and accommodate the specific and evolving needs of the industry.

Commenting upon the announcement, Daniel Perlman, CEO and Founder of RPS Inc. said “By combining RPS’ innovative approaches to meeting the industry’s needs with Asklep’s excellent reputation, significant size, and local infrastructure, RPS will be able to meet current and future needs across the biopharmaceutical and medical device industry.  Japan is an important market for clinical development and whilst other global CROs have struggled to establish themselves through either loose alliances or home-grown small operations, we have decided that a JVC with teeth brings true ownership and accountability with mutual success and long-term stability”.

Asklep continues to be committed to providing unique, high quality solutions for drug lifecycle management and we are determined to become the HUB for Pharmaceutical Intelligence in the Asian region through our strategic vision of “ACTION for ACTS (Asian Clinical Trials and Solutions)”.

Outline of JVC